Bristol-Myers Squibb Company (BMY)
NYSE: BMY · Real-Time Price · USD
56.39
-0.06 (-0.11%)
At close: May 13, 2026, 4:00 PM EDT
56.39
0.00 (0.00%)
After-hours: May 13, 2026, 5:42 PM EDT
BMY Revenue
Bristol-Myers Squibb Company had revenue of $11.49B in the quarter ending March 31, 2026, with 2.57% growth. This brings the company's revenue in the last twelve months to $48.48B, up 1.78% year-over-year. In the year 2025, Bristol-Myers Squibb Company had annual revenue of $48.19B, down -0.22%.
Revenue (ttm)
$48.48B
Revenue Growth
+1.78%
P/S Ratio
2.38
Revenue / Employee
$1,491,754
Employees
32,500
Market Cap
115.15B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 48.19B | -106.00M | -0.22% |
| Dec 31, 2024 | 48.30B | 3.29B | 7.32% |
| Dec 31, 2023 | 45.01B | -1.15B | -2.50% |
| Dec 31, 2022 | 46.16B | -226.00M | -0.49% |
| Dec 31, 2021 | 46.39B | 3.87B | 9.09% |
| Dec 31, 2020 | 42.52B | 16.37B | 62.62% |
| Dec 31, 2019 | 26.15B | 3.58B | 15.89% |
| Dec 31, 2018 | 22.56B | 1.79B | 8.59% |
| Dec 31, 2017 | 20.78B | 1.35B | 6.94% |
| Dec 31, 2016 | 19.43B | 2.87B | 17.31% |
| Dec 31, 2015 | 16.56B | 681.00M | 4.29% |
| Dec 31, 2014 | 15.88B | -506.00M | -3.09% |
| Dec 31, 2013 | 16.39B | -1.24B | -7.01% |
| Dec 31, 2012 | 17.62B | -3.62B | -17.05% |
| Dec 31, 2011 | 21.24B | 1.76B | 9.03% |
| Dec 31, 2010 | 19.48B | 676.00M | 3.59% |
| Dec 31, 2009 | 18.81B | 1.09B | 6.17% |
| Dec 31, 2008 | 17.72B | 2.10B | 13.43% |
| Dec 31, 2007 | 15.62B | -591.00M | -3.65% |
| Dec 31, 2006 | 16.21B | -2.40B | -12.88% |
| Dec 31, 2005 | 18.61B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Merck & Co. | 65.77B |
| Pfizer | 63.32B |
| AbbVie | 62.82B |
| AstraZeneca | 60.44B |
| Novartis AG | 56.58B |
| Sanofi | 54.60B |
| Novo Nordisk | 50.57B |
| GSK plc | 43.29B |
BMY News
- 1 day ago - Pacira BioSciences Sends Letter to Stockholders Reiterating Superior Qualifications of its Board Nominees - GlobeNewsWire
- 1 day ago - Bristol-Myers Squibb and China's Hengrui Pharma Forge Tie-Up - WSJ
- 1 day ago - Hengrui Pharma and Bristol Myers Squibb Announce Strategic Agreements to Advance Innovative Medicines Across Oncology, Hematology, and Immunology - PRNewsWire
- 1 day ago - China's Jiangsu Hengrui, Bristol Myers Squibb in deal worth up to $15.2 bln - Reuters
- 5 days ago - Bristol Myers announces EU approved Sotyktu to treat PsA - TheFly
- 5 days ago - Bristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib) for the Treatment of Active Psoriatic Arthritis in Adults - Business Wire
- 5 days ago - Bristol Myers using AI to boost drug production volume, NY Times reports - TheFly
- 7 days ago - Bristol Myers Squibb to Participate in the Bank of America Securities Healthcare Conference 2026 - Business Wire